RDY | Dr reddy's laboratories ltd - Stock Value & PE Ratio Analysis

3

24

15

Average Growth

AI analysis rates RDY with a medium value score of 3.
It is mainly due to adequate safety shown in the balance sheet, but with concerns regarding unstable operating cash flow.
Over the past 3 months, RDY has maintained a consecutive value rating of 3.0, slightly lower than the rating of 3.8 over the past 3 years, indicating decreasing growth opportunities for enterprise value.
Compared to all stocks in the Health Care sector, RDY has a medium value rating.

RDY Value Reference Factors

The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.

Update to 2025/02/13 (Weekly Update)

RDY Financial Forecast

Unit : USD

Update to 2025/5/9 (Quarterly Update)

RDY Earnings Table

Unit : USD

QTR	Non-GAAP EPS	EPS YoY	EPS Surprise %	Sales	Sales YoY	Sales Surprise %	NPM
Current	0.2	-4.8%	-9.1%	76.73B	9,243.7%	8,721.8%	18.5%
2024Q1	0.04	-81%	-9.8%	80.16B	9,589.3%	8,717.1%	18.1%
2023Q1	0.16	77.8%	33.3%	773.11M	17%	11.2%	22.8%
2022Q4	0.18	100%	50%	660.23M	2.4%	-2.8%	1.6%
2022Q3	0.11	-8.3%	-87.3%	717.19M	7.6%	5.7%	13.3%

Update to 2025/5/9 (Quarterly Update)

RDY Historical Value Score

You can use historical scores of 3 or above to observe potential performance and make investment decisions.

RDY Value Strategy Backtest

The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.

Entry

Exit

The Backtest Result of RDY from 2007/01 till Now

124.21%
Cumulative Return: 4.51%
Annual Return: 21.14%
Volatility: 0.21
Sharpe Ratio

Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from January, 2007 to May, 2025. (Total Trades: 2)